Pazopanib based drugs: price, availability and description

Pazopanib is a potent tyrosine kinase inhibitor that blocks tumor growth and the formation of new blood vessels (angiogenesis) supplying the tumor. It targets VEGF, PDGF, and c-KIT receptors. Pazopanib is a first-line standard of care for advanced renal cell carcinoma (RCC) and is also indicated for the treatment of soft tissue sarcoma (STS) in patients who have received prior chemotherapy.